Cargando…
Complete response in patient with liver metastasis of HER2-positive breast cancer following therapy with margetuximab: a case report
Metastatic human epidermal growth factor receptor 2 (HER2) positive breast cancer has a poor prognosis and few effective targeted therapies. However, several anti-HER2 agents are emerging in conjunction with chemotherapy, which may lead to increased rates of pathological complete response in patient...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344431/ https://www.ncbi.nlm.nih.gov/pubmed/36730303 http://dx.doi.org/10.1097/CAD.0000000000001466 |
_version_ | 1785072867755425792 |
---|---|
author | Chang, Haiyan Hu, Ting Hu, Jie Ding, Teng Wang, Qiong Cheng, Jing |
author_facet | Chang, Haiyan Hu, Ting Hu, Jie Ding, Teng Wang, Qiong Cheng, Jing |
author_sort | Chang, Haiyan |
collection | PubMed |
description | Metastatic human epidermal growth factor receptor 2 (HER2) positive breast cancer has a poor prognosis and few effective targeted therapies. However, several anti-HER2 agents are emerging in conjunction with chemotherapy, which may lead to increased rates of pathological complete response in patients with HER2-positive metastatic breast cancer. Among them, margetuximab demonstrated a significant improvement in progression-free survival compared with trastuzumab, when combined with chemotherapy in pretreated patients. Here we present a case of a 67-year-old female patient who was diagnosed with HER2-positive, histological grade III and invasive ductal carcinoma of the left breast in September 2018. She received postoperative adjuvant therapy with EC-TH plus radiotherapy, followed by therapy with HER2-targeted trastuzumab for 1 year (till December 2019). In May 2020, routine reexamination showed a supraclavicular lymph node and bone metastasis. Patient was then treated with pyrotinib, capecitabine and bisphosphonate for a period of 3 months. In December 2020, liver MRI revealed multiple liver metastases. The patient received eight cycles of second-line therapy (vinorelbine plus margetuximab) from January 2021. Since the ninth cycle, the patient was continued with only margetuximab. In March 2021, MRI showed a 70% decrease in the liver metastasis lesions. By June 2021, liver lesions were totally disappeared. During therapy, patient experienced only grade-1 anemia. This case demonstrates that margetuximab plus chemotherapy is safe and might bring clinical benefits for patients with HER2-positive breast cancer with liver metastasis. Further studies evaluating the efficacy and safety of margetuximab in Chinese HER2-positive breast cancer patients are needed. |
format | Online Article Text |
id | pubmed-10344431 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-103444312023-07-14 Complete response in patient with liver metastasis of HER2-positive breast cancer following therapy with margetuximab: a case report Chang, Haiyan Hu, Ting Hu, Jie Ding, Teng Wang, Qiong Cheng, Jing Anticancer Drugs Case Reports Metastatic human epidermal growth factor receptor 2 (HER2) positive breast cancer has a poor prognosis and few effective targeted therapies. However, several anti-HER2 agents are emerging in conjunction with chemotherapy, which may lead to increased rates of pathological complete response in patients with HER2-positive metastatic breast cancer. Among them, margetuximab demonstrated a significant improvement in progression-free survival compared with trastuzumab, when combined with chemotherapy in pretreated patients. Here we present a case of a 67-year-old female patient who was diagnosed with HER2-positive, histological grade III and invasive ductal carcinoma of the left breast in September 2018. She received postoperative adjuvant therapy with EC-TH plus radiotherapy, followed by therapy with HER2-targeted trastuzumab for 1 year (till December 2019). In May 2020, routine reexamination showed a supraclavicular lymph node and bone metastasis. Patient was then treated with pyrotinib, capecitabine and bisphosphonate for a period of 3 months. In December 2020, liver MRI revealed multiple liver metastases. The patient received eight cycles of second-line therapy (vinorelbine plus margetuximab) from January 2021. Since the ninth cycle, the patient was continued with only margetuximab. In March 2021, MRI showed a 70% decrease in the liver metastasis lesions. By June 2021, liver lesions were totally disappeared. During therapy, patient experienced only grade-1 anemia. This case demonstrates that margetuximab plus chemotherapy is safe and might bring clinical benefits for patients with HER2-positive breast cancer with liver metastasis. Further studies evaluating the efficacy and safety of margetuximab in Chinese HER2-positive breast cancer patients are needed. Lippincott Williams & Wilkins 2023-08 2022-11-23 /pmc/articles/PMC10344431/ /pubmed/36730303 http://dx.doi.org/10.1097/CAD.0000000000001466 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Case Reports Chang, Haiyan Hu, Ting Hu, Jie Ding, Teng Wang, Qiong Cheng, Jing Complete response in patient with liver metastasis of HER2-positive breast cancer following therapy with margetuximab: a case report |
title | Complete response in patient with liver metastasis of HER2-positive breast cancer following therapy with margetuximab: a case report |
title_full | Complete response in patient with liver metastasis of HER2-positive breast cancer following therapy with margetuximab: a case report |
title_fullStr | Complete response in patient with liver metastasis of HER2-positive breast cancer following therapy with margetuximab: a case report |
title_full_unstemmed | Complete response in patient with liver metastasis of HER2-positive breast cancer following therapy with margetuximab: a case report |
title_short | Complete response in patient with liver metastasis of HER2-positive breast cancer following therapy with margetuximab: a case report |
title_sort | complete response in patient with liver metastasis of her2-positive breast cancer following therapy with margetuximab: a case report |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344431/ https://www.ncbi.nlm.nih.gov/pubmed/36730303 http://dx.doi.org/10.1097/CAD.0000000000001466 |
work_keys_str_mv | AT changhaiyan completeresponseinpatientwithlivermetastasisofher2positivebreastcancerfollowingtherapywithmargetuximabacasereport AT huting completeresponseinpatientwithlivermetastasisofher2positivebreastcancerfollowingtherapywithmargetuximabacasereport AT hujie completeresponseinpatientwithlivermetastasisofher2positivebreastcancerfollowingtherapywithmargetuximabacasereport AT dingteng completeresponseinpatientwithlivermetastasisofher2positivebreastcancerfollowingtherapywithmargetuximabacasereport AT wangqiong completeresponseinpatientwithlivermetastasisofher2positivebreastcancerfollowingtherapywithmargetuximabacasereport AT chengjing completeresponseinpatientwithlivermetastasisofher2positivebreastcancerfollowingtherapywithmargetuximabacasereport |